Clinical Impact of 5  Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

ConclusionIn patients prolonging treatment with liraglutide for 5  years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research